AstraZeneca PLC (AZN) Financial Statements
Historical financial data — 5 statements covering FY2021–FY2025
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% o...
AstraZeneca PLC's revenue increased 8.6% year over year, from $54.07B to $58.74B.
Net income increased 45.3% over the same period, from $7.04B to $10.22B.
Over the 4-year period from FY2021 to FY2025, revenue grew by 57% in total.
Total debt increased by 8.9% to $32.35B.
The debt-to-equity ratio stands at 0.64, indicating a moderate leverage profile.
Operating cash flow declined 6.0% to $13.70B.
AstraZeneca PLC maintains a healthy net profit margin of 17.4%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2021 | $37.42B | $112.0M | $25.41B | $2.90B | $9.81B | $96.48B | $31.14B | $37.06B |
| FY2022 | $44.35B+18.5% | $3.29B | $35.71B | $8.81B | $10.35B | $101.12B | $29.65B | $39.17B |
| FY2023 | $45.81B+3.3% | $5.96B | $37.77B | $9.70B | $11.86B | $104.03B | $30.46B | $40.87B |
| FY2024 | $54.07B+18.0% | $7.04B | $44.44B | $12.93B | $14.57B | $114.07B | $29.70B | $48.72B |
| FY2025 | $58.74B+8.6% | $10.22B | $47.99B | $14.29B | $13.70B | $115.83B | $32.35B | $50.37B |
Balance Sheet Summary (FY2025)
AstraZeneca PLC (AZN) Financial Statements & Revenue History
AstraZeneca PLC (AZN) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry trading at $164.21 with a market capitalization of $255. This page provides 5 historical financial statements for AstraZeneca PLC, including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, AstraZeneca PLC reported revenue of $58.7 billion, representing 8.6% year-over-year growth. The net profit margin of 17.4% reflects strong profitability. The debt-to-equity ratio of 0.64 reflects moderate leverage.
AZN Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows AstraZeneca PLC's revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether AZN is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track AZN's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently AstraZeneca PLC converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of AZN's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use AZN Financial Data
Investors use AstraZeneca PLC's financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare AZN's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how AZN's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View AZN's financial health score, earnings, and pre-market pricing.
Financial data is sourced from AstraZeneca PLC's SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.AZN trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.